Prof. Kwangsuk Lim | Biopharmaceuticals | Best Researcher Award

Asoociate Professor at Kangwon National University | South Korea

Prof. Kwang Suk Lim, Ph.D., is an accomplished Associate Professor in the Department of Biotechnology and Bioengineering at Kangwon National University, South Korea, whose research spans biotechnology, nanomedicine, and bioengineering with a strong focus on cancer immunotherapy, targeted drug delivery, and biopolymer applications. His work emphasizes the development of recombinant fusion proteins, nanocomplexes, and chimeric antigen receptor (CAR)-based strategies for enhancing immune-cell therapeutics. He has also contributed to advancing chemo-immunotherapy platforms, surface-engineered natural killer (NK) cells, and the application of metal–organic frameworks for microplastic degradation and environmental protection. Dr. Lim’s interdisciplinary research has been published in high-impact journals such as Pharmaceutics, Biomedicine & Pharmacotherapy, and Environmental Pollution, reflecting his leadership in translational biomedical innovation. His scientific record includes 25 Scopus-indexed publications with 260 citations by 251 documents and an h-index of 9, alongside multiple Korean and international patents in biomaterials, recombinant protein therapeutics, and drug delivery technologies. He has been recognized with several honors, including the Kangwon National University Teaching Award and the Bioengineering Researcher Award, underscoring his excellence in both academic and research achievements.

Profile: Scopus | ORCID

Featured Publications

Lim, S. Y., Kim, Y., Han, S., Kim, H.-O., Ha, S.-J., Park, J.-A., Yun, J., Chae, S., Won, Y.-W., & Lim, K. S. (2025). CliCAR: A non-genetic CAR engineering strategy to empower NK cells for targeted cancer immunotherapy. Biomedicine & Pharmacotherapy, 193, 118691.

Kim, Y., Kwak, J., Lim, M., Lim, S. Y., Chae, S., Ha, S.-J., Won, Y.-W., Kim, H.-O., & Lim, K. S. (2025). Advances in PCL, PLA, and PLGA-based technologies for anticancer drug delivery. Pharmaceutics, 17, 1354.

Lim, S. Y., Kim, Y., Kim, H., Han, S., Yun, J., Kim, H.-O., Ha, S.-J., Chae, S., Won, Y.-W., & Lim, K. S. (2025). Surface engineering of natural killer cells with lipid-based antibody capture platform for targeted chemoimmunotherapy. Pharmaceutics, 17(10), 1285.

Kim, Y., Lim, S. Y., Kim, H.-O., Ha, S.-J., Park, J.-A., Won, Y.-W., Chae, S., & Lim, K. S. (2025). Combination strategies with HSP90 inhibitors in cancer therapy: Mechanisms, challenges, and future perspectives. Pharmaceuticals, 18(8), 1083.

Lim, S. Y., Han, S., Kim, Y., Kim, H., Kim, Y., Park, J.-A., Yun, J., Yong, S.-B., Won, Y.-W., & Lim, K. S. (2025). Advanced breast cancer immunotherapy: Surface modification of NK cells for embedding antibody-drug conjugates. Biomedicine & Pharmacotherapy, 189, 118245.